TrialThe Journal of clinical investigation2022

One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.

Sixten Körper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.